MaxCyte, Inc. (MXCT) Spending and interest coverage
- R&D / revenue · 12 months: Value 89.03%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 26.35%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 89.03% | Research and development expense / revenue. Period ending 2026-06-30. $16.76M ÷ $18.83M × 100 ≈ 89.03% |
| Stock-based compensation / revenue · 12 months | 26.35% | Share-based compensation / revenue. Period ending 2026-06-30. $4.96M ÷ $18.83M × 100 ≈ 26.35% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 16.76M USD | Research and Development Expense |
| Revenue | 18.83M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 4.96M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -41.79M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.76M | $18.83M | $4.96M | $-41.79M | (m) | 89.03% | 26.35% | (m) | (m) |
| 2026-03-31 | $18.78M | $19.71M | $7.32M | $-45.79M | (m) | 95.24% | 37.10% | (m) | (m) |
| 2025-12-31 | $20.82M | $20.96M | $9.21M | $-51.90M | (m) | 99.36% | 43.96% | (m) | (m) |
| 2025-09-30 | $22.10M | $22.23M | $11.64M | $-53.57M | (m) | 99.45% | 52.38% | (m) | (m) |
| 2025-06-30 | $22.10M | $23.23M | $13.06M | $-53.48M | (m) | 95.13% | 56.20% | (m) | (m) |
| 2025-03-31 | $21.45M | $22.37M | $13.11M | $-51.22M | (m) | 95.88% | 58.58% | (m) | (m) |
| 2024-12-31 | $22.23M | $22.21M | $13.08M | $-51.20M | (m) | 100.05% | 58.89% | (m) | (m) |
| 2024-09-30 | $23.45M | $20.92M | $13.52M | $-46.39M | (m) | 112.14% | 64.65% | (m) | (m) |
| 2024-06-30 | $24.40M | $19.46M | $13.76M | $-46.29M | (m) | 125.40% | 70.72% | (m) | (m) |
| 2024-03-31 | $24.45M | $20.12M | $13.72M | $-47.40M | (m) | 121.53% | 68.19% | (m) | (m) |
| 2023-12-31 | $23.82M | $19.50M | $13.98M | $-48.30M | (m) | 122.16% | 71.70% | (m) | (m) |
| 2023-09-30 | $23.70M | $22.50M | $13.52M | $-46.95M | (m) | 105.35% | 60.11% | (m) | (m) |
| 2023-06-30 | $22.76M | $25.50M | $13.11M | $-40.71M | (m) | 89.29% | 51.43% | (m) | (m) |
| 2023-03-31 | $21.80M | $26.86M | $12.57M | $-36.38M | (m) | 81.16% | 46.79% | (m) | (m) |
| 2022-12-31 | $19.51M | $28.75M | $11.75M | $-27.36M | (m) | 67.88% | 40.88% | (m) | (m) |
| 2022-09-30 | $17.17M | $28.50M | $11.08M | $-25.57M | (m) | 60.24% | 38.89% | (m) | (m) |
| 2022-06-30 | $14.59M | $26.95M | $10.17M | $-20.30M | (m) | 54.12% | 37.73% | (m) | (m) |
| 2022-03-31 | $13.10M | $24.19M | $9.10M | $-15.97M | (m) | 54.14% | 37.63% | (m) | (m) |
| 2021-12-31 | $15.41M | $21.57M | $7.96M | $-18.19M | $5.40K | 71.42% | 36.90% | -3368.26× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $17.73M | $15.45M | $2.47M | $-11.06M | $21.70K | 114.78% | 16.00% | -509.53× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $17.59M | $13.26M | $1.75M | $-12.42M | $51.90K | 132.70% | 13.22% | -239.31× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |